Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J RIIS

Showing results (101-110 of 128) with videos related to

Pageof 13
Sort By:
Acta Medica Scandinavica|January 1, 1987
Bone metabolism and bone status in osteoporotic patientsD Hartwell, B J Riis, C Christiansen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 1, 1990
Dual-energy x-ray absorptiometry: a precise method of measuring bone mineral density in the lumbar spineM A Hansen, C Hassager, K Overgaard, et al.
Maturitas|November 1, 1987
Climacteric symptoms after oral and percutaneous hormone replacement therapyP B Jensen, J Jensen, B J Riis, et al.
Acta Endocrinologica|June 1, 1990
Vitamin D metabolism in osteoporotic women during treatment with estrogen, an anabolic steroid, or calcitoninD Hartwell, C Hassager, K Overgaard, et al.
The Journal of Clinical Endocrinology and Metabolism|October 1, 1988
The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolismJ S Johansen, B J Riis, C Hassager, et al.
Metabolism: Clinical and Experimental|March 1, 1989
Changes in soft tissue body composition and plasma lipid metabolism during nandrolone decanoate therapy in postmenopausal osteoporotic womenC Hassager, J Pødenphant, B J Riis, et al.
The Journal of Clinical Endocrinology and Metabolism|July 1, 1990
Serum bone Gla protein: a potential marker of growth hormone (GH) deficiency and the response to GH therapyJ S Johansen, S B Jensen, B J Riis, et al.
Maturitas|March 22, 2003
Adverse effects of a SERM (Levormeloxifene). Safety parameters and bone mineral density 12 months after treatment withdrawalL Warming, C Christoffersen, B J Riis, et al.
Bone and Mineral|April 1, 1989
Treatment of postmenopausal osteoporosis: is the anabolic steroid nandrolone decanoate a candidate?J S Johansen, C Hassager, J Pødenphant, et al.
British Journal of Clinical Pharmacology|April 18, 2009
Influence of food intake on the bioavailability and efficacy of oral calcitoninMorten A Karsdal, Inger Byrjalsen, Möise Azria, et al.
Pageof 13

Showing results (101-110 of 128) with videos related to

Sort By:
Pageof 13
Acta Medica Scandinavica|January 1, 1987
Bone metabolism and bone status in osteoporotic patientsD Hartwell, B J Riis, C Christiansen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 1, 1990
Dual-energy x-ray absorptiometry: a precise method of measuring bone mineral density in the lumbar spineM A Hansen, C Hassager, K Overgaard, et al.
Maturitas|November 1, 1987
Climacteric symptoms after oral and percutaneous hormone replacement therapyP B Jensen, J Jensen, B J Riis, et al.
Acta Endocrinologica|June 1, 1990
Vitamin D metabolism in osteoporotic women during treatment with estrogen, an anabolic steroid, or calcitoninD Hartwell, C Hassager, K Overgaard, et al.
The Journal of Clinical Endocrinology and Metabolism|October 1, 1988
The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolismJ S Johansen, B J Riis, C Hassager, et al.
Metabolism: Clinical and Experimental|March 1, 1989
Changes in soft tissue body composition and plasma lipid metabolism during nandrolone decanoate therapy in postmenopausal osteoporotic womenC Hassager, J Pødenphant, B J Riis, et al.
The Journal of Clinical Endocrinology and Metabolism|July 1, 1990
Serum bone Gla protein: a potential marker of growth hormone (GH) deficiency and the response to GH therapyJ S Johansen, S B Jensen, B J Riis, et al.
Maturitas|March 22, 2003
Adverse effects of a SERM (Levormeloxifene). Safety parameters and bone mineral density 12 months after treatment withdrawalL Warming, C Christoffersen, B J Riis, et al.
Bone and Mineral|April 1, 1989
Treatment of postmenopausal osteoporosis: is the anabolic steroid nandrolone decanoate a candidate?J S Johansen, C Hassager, J Pødenphant, et al.
British Journal of Clinical Pharmacology|April 18, 2009
Influence of food intake on the bioavailability and efficacy of oral calcitoninMorten A Karsdal, Inger Byrjalsen, Möise Azria, et al.
Pageof 13